Inozyme Pharma Inc. (INZY): Price-to-Sales Ratio

Corporate company logo of Inozyme Pharma, Inc. (INZY)

Inozyme Pharma, Inc. (INZY) operations are protected by FDA and EMA regulators, which minimizes external risks. The company is developing a unique drug, INZ-701, that addresses the genetic causes of tissue calcification in children. Development is being conducted through partnerships with leading scientific centers. The company's market cap-to-revenue ratio clearly demonstrates the asset's consolidation phases, and captures the current value of the indicator.

INZY: inozyme.com P/S Multiple 07/04/2022 - 11/13/2026

Metric breakdowns and analytics for Inozyme Pharma, Inc. (INZY)

- share price and consensus valuation forecast:
Price Performance Chart inozyme.com|INZY - Price Target Chart
- stock exchange capitalization data:
Market Valuation Inozyme|INZY - Enterprise Value
- balance sheet net asset value indicators:
Accounting Value of a Share Inozyme Pharma|INZY - Book Capitalization|Market Capitalization to Book Value Ratio inozyme.com|INZY - Aggregate Company Assets
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Inozyme Pharma, Inc.|INZY - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio inozyme.com|INZY - Company Aggregate Debts|Debts to Book Capitalization Inozyme|INZY - Company Long-Term Debts|Short-Term Debt Volume Inozyme Pharma|Immediate Liquidity Ratio inozyme.com
- earnings and valuation multiples information:
INZY - Company Net Income|Expected Net Profit Inozyme Pharma, Inc.|INZY - Price to Earnings Ratio|Price to Expected Earnings Ratio inozyme.com|INZY - Price/Earnings to Growth Multiple|Company Value to EBITDA Inozyme|INZY - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Inozyme Pharma|INZY - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months inozyme.com|INZY - Net earnings per share growth this year|Expected earnings per share trend next year Inozyme Pharma, Inc.
- issuer revenue and sales details:
INZY - Company Revenue|Company Expected Revenue inozyme.com|INZY - P/S Multiple|Forward Price to Sales Inozyme
General company analysis:INZY Inozyme Pharma Inc.
Finished products of Inozyme Pharma

The P/S multiple determines the market value of a business relative to its annual turnover, allowing for an assessment of an asset's overvaluation through the ratio of share price to revenue per share. For Inozyme Pharma, Inc. (INZY), this indicator reflects the speculative value of future successes in orphan disease therapy, where the company's valuation precedes actual sales pending the confirmation of drug efficacy during clinical trials.

Competing companies

VRTX (vrtx.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Alnylam ALNY|INSM (Insmed Inc.) - Price-to-Sales Ratio|United Therapeutics Corp. - P/S Multiple|Market Capitalization-to-Revenue Ratio BMRN (BioMarin Corp)|BBIO: P/S Multiple|BGM Group (BGM) - P/S Multiple|Price-to-Revenue Ratio Cogent Biosciences, Inc.|XERS: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Keros Pharma (KROS)|Market Cap to Revenue Arcturus Corp ARCT|P/S Multiple ETON (Eton Pharmaceuticals)|P/S Multiple kamada.com KMDA|Fulcrum Therapeutics, Inc. - P/S Multiple|Price-to-Revenue Coefficient Abeona Therapeutics ABEO|mereobiopharma.com (MREO) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio PLX|Price-to-Revenue Ratio Pliant Therapeutics Inc|Price to Sales appliedtherapeutics.com APLT|Market Cap to Revenue RNTX (Rein Therapeutics)|GELS: Price-to-Sales Ratio|Aytu BioPharma - Market Cap to Revenue|Chemomab Therapeutics Ltd (CMMB) - Price to Sales|SRXH - Price-to-Revenue Ratio|Polyrizon Ltd (PLRZ) - Market Cap to Revenue|AEZS: P/S Multiple|Price to Sales Cyclo Therapeutics Inc. (CYTH)|Market Cap to Revenue RPHM|CSCI: Market Capitalization-to-Revenue Ratio